Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

ABT - Abbott Laboratories So'nggi Yangiliklar | Finranks

Home

/

ABT

A

Abbott Laboratories (ABT)

NYQ – Real vaqt narxi. Valyuta: USD

84.35

+1.79 (2.17%)

Yopilishda: May 12, 2026, 4:00 PM EDT

84.40

+0.05 (0.06%)

Bozordan keyin: May 12, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Abbott: Three Supercycles, Mispriced At A 10-Year Low

Abbott: Three Supercycles, Mispriced At A 10-Year Low

Abbott Laboratories trades at a decade low of 17.7x forward earnings despite 13.2% Q1 2026 Medical Devices growth and a 54-year dividend streak. Three underappreciated catalysts—Exact Sciences synergy, CMS CGM expansion, and Nutrition margin recovery—could drive $1.27–$1.73 incremental EPS by 2028–2029. Consensus underestimates ABT's commercial leverage, with distribution synergies and CMS reimbursement expansion offering asymmetric upside not priced into current models.

Abbott Laboratories Is On Sale, Don't Overlook It

Abbott Laboratories Is On Sale, Don't Overlook It

Abbott Laboratories is trading at a 27% discount to fair value, offering a compelling entry point for long-term investors. ABT's Medical Devices and Diagnostics segments drive robust growth, with the Exact Sciences acquisition adding market-leading oncology diagnostics. Consensus forecasts 9.1% annual EPS growth through 2028, supporting continued 7%-8% dividend growth and a 54-year streak.

Abbott's Medical Device Strategy Supports Long-Term Growth Outlook

Abbott's Medical Device Strategy Supports Long-Term Growth Outlook

ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.

Got $5,000? These 3 High-Yielding Stocks Are Trading Near Their 52-Week Lows

Got $5,000? These 3 High-Yielding Stocks Are Trading Near Their 52-Week Lows

These stocks all yield more than 2%. These companies have also been increasing their payouts for decades.

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Polen Focus Growth Portfolio Q1 2026 Portfolio Update

Polen Focus Growth Portfolio Q1 2026 Portfolio Update

In Q1 2026, Polen Focus Growth Portfolio returned -17.27% (net of fees) compared to -9.78% for the Index. Starbucks was the top performing absolute and relative contributor in Q1 amid positive signs that CEO Brian Nicol's multi-year turnaround strategy is beginning to bear fruit. In Q1 2026, we initiated new positions in Lam Research, Meta and Rollins, while we sold our holdings in Abbott Laboratories, Adobe, and Boston Scientific, Paycom and Intuit.

Videolar

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

Cramer's Mad Dash: Abbott Labs

Press-relizlar

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated insights through the artery The integrated imaging platform is designed to enable fast, intuitive decision making for physicians while treating complex coronary disease to open clogged arteries The AI enabled software helps physicians size and position the stent more accurately, which can lead to better results for patients ABBOTT PARK, Ill., April 28, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next-generation Ultreon™ 3.0 Software.

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

President Trump demands drugmakers slash prices within 60 days

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

Four late-breaking presentations at Heart Rhythm Society 2026 in Chicago highlight strong clinical evidence across Abbott's growing pulsed field ablation and novel cardiac pacing portfolios Six-month results from the FlexPulse IDE study for the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, reveal positive outcomes for treating complex AFib cases New data from the Volt CE Mark Extension Cohort trial for the Volt™ PFA System, demonstrate the strong safety, efficacy and efficiency of treatment of AFib cases for posterior wall ablation Two new conduction system pacing studies showcase initial results of Abbott's investigational UltiSynq™ CSP implantable cardioverter-defibrillator lead and a first-in-human evaluation of the investigational AVEIR™ CSP leadless pacemaker system ABBOTT PARK, Ill., April 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new late-breaking data from four trials that demonstrate strong clinical outcomes within its pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios to treat heart rhythm disorders.

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCED ABBOTT PARK, Ill., April 17, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will present new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating continued advancements in its multi-biomarker, multi-cancer early detection (MCED) program supporting the commercially available Cancerguard® test.

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

First-quarter GAAP diluted EPS of $0.61; adjusted diluted EPS of $1.15 reflects growth of 6 percent Completed acquisition of Exact Sciences, establishing Abbott as a leader in the fast-growing oncology diagnostics market Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1 Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58, which includes $0.20 of dilution related to the acquisition of Exact Sciences ABBOTT PARK, Ill., April 16, 2026 /PRNewswire/ -- Abbott today (NYSE: ABT) announced financial results for the first quarter ended March 31, 2026.